Scleroderma renal crisis

Nilanjana Bose, Andres Chiesa-Vottero, Soumya Chatterjee

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Objectives: To discuss the pathophysiology, risk factors, clinical manifestations, diagnosis, treatment, prevention, and outcomes of scleroderma renal crisis (SRC), a serious yet potentially treatable complication of scleroderma (systemic sclerosis). Methods: A PubMed search for articles published up until April 2014 was conducted using the following keywords: scleroderma, systemic sclerosis, scleroderma renal crisis, renal, treatment, and prognosis. Literature was carefully reviewed, and different risk factors, treatment options, prognostic factors, and survival data were assessed. Results: SRC occurs in about 10% of all patients with scleroderma. It is characterized by malignant hypertension and progressive renal failure. Around 10% of SRC cases may present with normal blood pressure, termed normotensive renal crisis. The etiopathogenesis is presumed to be a series of insults to the kidneys resulting in endothelial injury, intimal proliferation, and narrowing of renal arterioles leading to decreased blood flow, hyperplasia of the juxtaglomerular apparatus, hyperreninemia, and accelerated hypertension. Risk factors include rapid skin thickening, use of certain medications such corticosteroids or cyclosporine, new-onset microangiopathic hemolytic anemia and/or thrombocytopenia, cardiac complications (pericardial effusion, congestive heart failure, and/or arrhythmias), large joint contractures, and presence of anti-RNA polymerase III antibody. Since the 1970s, with the advent of angiotensin-converting enzyme (ACE) inhibitors, mortality associated with SRC decreased from 76% to <10%. Some patients may progress to end-stage renal disease and need dialysis. Renal transplantation has improved survival, though SRC may recur in transplanted kidneys. Conclusions: More than 60 years after its initial description, SRC still remains an important cause of morbidity and mortality in scleroderma. Since the advent of ACE inhibitors, the prognosis of SRC has improved substantially. Prompt diagnosis and treatment may help prevent adverse outcomes and improve survival.

Original languageEnglish (US)
Pages (from-to)687-694
Number of pages8
JournalSeminars in Arthritis and Rheumatism
Volume44
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Kidney
Systemic Scleroderma
Angiotensin-Converting Enzyme Inhibitors
Survival
Juxtaglomerular Apparatus
Tunica Intima
Malignant Hypertension
RNA Polymerase III
Pericardial Effusion
Mortality
Hemolytic Anemia
Arterioles
Contracture
PubMed
Thrombocytopenia
Kidney Transplantation
Cyclosporine
Chronic Kidney Failure
Hyperplasia
Renal Insufficiency

Keywords

  • Angiotensin-converting enzyme inhibitor
  • Scleroderma
  • Scleroderma renal crisis
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

Bose, N., Chiesa-Vottero, A., & Chatterjee, S. (2015). Scleroderma renal crisis. Seminars in Arthritis and Rheumatism, 44(6), 687-694. https://doi.org/10.1016/j.semarthrit.2014.12.001

Scleroderma renal crisis. / Bose, Nilanjana; Chiesa-Vottero, Andres; Chatterjee, Soumya.

In: Seminars in Arthritis and Rheumatism, Vol. 44, No. 6, 01.06.2015, p. 687-694.

Research output: Contribution to journalReview article

Bose, N, Chiesa-Vottero, A & Chatterjee, S 2015, 'Scleroderma renal crisis', Seminars in Arthritis and Rheumatism, vol. 44, no. 6, pp. 687-694. https://doi.org/10.1016/j.semarthrit.2014.12.001
Bose, Nilanjana ; Chiesa-Vottero, Andres ; Chatterjee, Soumya. / Scleroderma renal crisis. In: Seminars in Arthritis and Rheumatism. 2015 ; Vol. 44, No. 6. pp. 687-694.
@article{7aa28eae9e4542aca9564f2538a8f71d,
title = "Scleroderma renal crisis",
abstract = "Objectives: To discuss the pathophysiology, risk factors, clinical manifestations, diagnosis, treatment, prevention, and outcomes of scleroderma renal crisis (SRC), a serious yet potentially treatable complication of scleroderma (systemic sclerosis). Methods: A PubMed search for articles published up until April 2014 was conducted using the following keywords: scleroderma, systemic sclerosis, scleroderma renal crisis, renal, treatment, and prognosis. Literature was carefully reviewed, and different risk factors, treatment options, prognostic factors, and survival data were assessed. Results: SRC occurs in about 10{\%} of all patients with scleroderma. It is characterized by malignant hypertension and progressive renal failure. Around 10{\%} of SRC cases may present with normal blood pressure, termed normotensive renal crisis. The etiopathogenesis is presumed to be a series of insults to the kidneys resulting in endothelial injury, intimal proliferation, and narrowing of renal arterioles leading to decreased blood flow, hyperplasia of the juxtaglomerular apparatus, hyperreninemia, and accelerated hypertension. Risk factors include rapid skin thickening, use of certain medications such corticosteroids or cyclosporine, new-onset microangiopathic hemolytic anemia and/or thrombocytopenia, cardiac complications (pericardial effusion, congestive heart failure, and/or arrhythmias), large joint contractures, and presence of anti-RNA polymerase III antibody. Since the 1970s, with the advent of angiotensin-converting enzyme (ACE) inhibitors, mortality associated with SRC decreased from 76{\%} to <10{\%}. Some patients may progress to end-stage renal disease and need dialysis. Renal transplantation has improved survival, though SRC may recur in transplanted kidneys. Conclusions: More than 60 years after its initial description, SRC still remains an important cause of morbidity and mortality in scleroderma. Since the advent of ACE inhibitors, the prognosis of SRC has improved substantially. Prompt diagnosis and treatment may help prevent adverse outcomes and improve survival.",
keywords = "Angiotensin-converting enzyme inhibitor, Scleroderma, Scleroderma renal crisis, Systemic sclerosis",
author = "Nilanjana Bose and Andres Chiesa-Vottero and Soumya Chatterjee",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.semarthrit.2014.12.001",
language = "English (US)",
volume = "44",
pages = "687--694",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Scleroderma renal crisis

AU - Bose, Nilanjana

AU - Chiesa-Vottero, Andres

AU - Chatterjee, Soumya

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objectives: To discuss the pathophysiology, risk factors, clinical manifestations, diagnosis, treatment, prevention, and outcomes of scleroderma renal crisis (SRC), a serious yet potentially treatable complication of scleroderma (systemic sclerosis). Methods: A PubMed search for articles published up until April 2014 was conducted using the following keywords: scleroderma, systemic sclerosis, scleroderma renal crisis, renal, treatment, and prognosis. Literature was carefully reviewed, and different risk factors, treatment options, prognostic factors, and survival data were assessed. Results: SRC occurs in about 10% of all patients with scleroderma. It is characterized by malignant hypertension and progressive renal failure. Around 10% of SRC cases may present with normal blood pressure, termed normotensive renal crisis. The etiopathogenesis is presumed to be a series of insults to the kidneys resulting in endothelial injury, intimal proliferation, and narrowing of renal arterioles leading to decreased blood flow, hyperplasia of the juxtaglomerular apparatus, hyperreninemia, and accelerated hypertension. Risk factors include rapid skin thickening, use of certain medications such corticosteroids or cyclosporine, new-onset microangiopathic hemolytic anemia and/or thrombocytopenia, cardiac complications (pericardial effusion, congestive heart failure, and/or arrhythmias), large joint contractures, and presence of anti-RNA polymerase III antibody. Since the 1970s, with the advent of angiotensin-converting enzyme (ACE) inhibitors, mortality associated with SRC decreased from 76% to <10%. Some patients may progress to end-stage renal disease and need dialysis. Renal transplantation has improved survival, though SRC may recur in transplanted kidneys. Conclusions: More than 60 years after its initial description, SRC still remains an important cause of morbidity and mortality in scleroderma. Since the advent of ACE inhibitors, the prognosis of SRC has improved substantially. Prompt diagnosis and treatment may help prevent adverse outcomes and improve survival.

AB - Objectives: To discuss the pathophysiology, risk factors, clinical manifestations, diagnosis, treatment, prevention, and outcomes of scleroderma renal crisis (SRC), a serious yet potentially treatable complication of scleroderma (systemic sclerosis). Methods: A PubMed search for articles published up until April 2014 was conducted using the following keywords: scleroderma, systemic sclerosis, scleroderma renal crisis, renal, treatment, and prognosis. Literature was carefully reviewed, and different risk factors, treatment options, prognostic factors, and survival data were assessed. Results: SRC occurs in about 10% of all patients with scleroderma. It is characterized by malignant hypertension and progressive renal failure. Around 10% of SRC cases may present with normal blood pressure, termed normotensive renal crisis. The etiopathogenesis is presumed to be a series of insults to the kidneys resulting in endothelial injury, intimal proliferation, and narrowing of renal arterioles leading to decreased blood flow, hyperplasia of the juxtaglomerular apparatus, hyperreninemia, and accelerated hypertension. Risk factors include rapid skin thickening, use of certain medications such corticosteroids or cyclosporine, new-onset microangiopathic hemolytic anemia and/or thrombocytopenia, cardiac complications (pericardial effusion, congestive heart failure, and/or arrhythmias), large joint contractures, and presence of anti-RNA polymerase III antibody. Since the 1970s, with the advent of angiotensin-converting enzyme (ACE) inhibitors, mortality associated with SRC decreased from 76% to <10%. Some patients may progress to end-stage renal disease and need dialysis. Renal transplantation has improved survival, though SRC may recur in transplanted kidneys. Conclusions: More than 60 years after its initial description, SRC still remains an important cause of morbidity and mortality in scleroderma. Since the advent of ACE inhibitors, the prognosis of SRC has improved substantially. Prompt diagnosis and treatment may help prevent adverse outcomes and improve survival.

KW - Angiotensin-converting enzyme inhibitor

KW - Scleroderma

KW - Scleroderma renal crisis

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84921328359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921328359&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2014.12.001

DO - 10.1016/j.semarthrit.2014.12.001

M3 - Review article

C2 - 25613774

AN - SCOPUS:84921328359

VL - 44

SP - 687

EP - 694

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 6

ER -